Flagship Pioneering

We’re honored to announce that our CLIPS device has been recognized with a 2025 AE50 Award, celebrating the year’s top innovations in agricultural, food, and biological systems! 🎉 This prestigious recognition from ASABE - American Society of Agricultural and Biological Engineers highlights our commitment to empowering farmers and retailers with technology that helps their bottom line. The CLIPS device represents a leap forward in supporting more efficient and sustainable farming—helping to protect our planet while increasing productivity. 🌎💡 We’re proud to be part of a community driving innovation for a more resilient future. Congrats to all winners of the 2025 AE50 award! ➡️ https://hubs.li/Q030hZkv0

We’re thrilled to announce that our groundbreaking research on the potential of our hypoimmune (HIP) platform technology has been accepted for publication in iScience!   The paper, “The HIP mouse and all of its organs are completely invisible to allogeneic immune cells,” demonstrates a remarkable breakthrough: the hypoimmune edits, previously shown to work in specific cell types like T cells, islets, cardiomyocytes, endothelial, and smooth muscle cells, are effective across an entire organism.   In this study, we successfully created a whole hypoimmune mouse and uncovered three key findings: Safety: Mice are born healthy, and reproduction is unaffected. Health: The mice remain healthy throughout their lifespan. Immune Evasion: The entire body—organs, tissues, and all—avoids immune rejection in the parabiosis model. This achievement represents a significant leap forward in our understanding of immune evasion and the potential of the HIP platform to revolutionize transplantation, regenerative medicine, and beyond. Congratulations to the entire team for this extraordinary milestone! Together, we’re changing what’s possible for patients. Read the full paper here: https://lnkd.in/gYreqbjz   #Innovation #Hypoimmune #CellTherapy #ImmuneEvasion #Sana #iScience

The staff at West End House is excited to see the toys start to pile up, thanks to the Toy Drive donations from Flagship Pioneering! Thank you, #HolidayHelpers, for your commitment to giving back!

Today, Samsung Biologics announced an investment through its Life Science Fund, highlighting confidence in our platform and team to advance therapeutic discovery with #GenerativeAI. This funding supports our efforts to design novel protein-based medicines and tackle some of the toughest challenges in human health. Samsung Biologics CEO John Rim emphasized the importance of leveraging innovation in #AI and #MachineLearning to build an ecosystem for next-generation therapeutic development, manufacturing, and R&D collaboration. With clinical programs already underway and plans to add three to six more in the next 18 months, we’re turning technological promise into tangible outcomes for patients. Learn more about Samsung’s investment: https://lnkd.in/ejv2X5CJ #ProgrammingBiology | #NowWeCan

Delighted that #NatureImmunology published our article describing the discovery and function of a novel KIR+ CD8+ regulatory T cell in #tumors from #melanoma patients. Conducted in collaboration with Yale School of Medicine and using our proprietary DECODE™ platform to determine the specificity of T cells in the tumor, we gained unique insights into the role of KIR+ CD8+ regulatory T cells as mediators of immune evasion in #cancer and other factors associated with clinical outcomes in patients. #tcell #DECODE   Congratulations to the Repertoire team, David Hafler, and the entire Yale team.   Read it here: https://lnkd.in/eWH5DcUQ